Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gilead Plays Up Its Strength As Market Awaits Business Development Moves

Executive Summary

Hiring new head of oncology away from Novartis has some watchers expecting cancer-focused business development by Gilead, but the company still thinks it can grow its HCV and HIV franchises and win the day with multiple candidates in NASH.

You may also be interested in...



Gilead Admits It Needs M&A To Resume Growth, But Stays Quiet

Sharply declining HCV sales, three upcoming patent expirations and a lack of near-term pipeline prospects other than HIV candidate bictegravir leave the specialty firm needing to spend some of its gigantic cash reserves on assets to revitalize its portfolio and/or stimulate the R&D engine.

Intercept’s NASH Phase III Enrolling Slowly; Gilead Could Gain Ground

As Gilead’s ASK1 inhibitor nears Phase III, Intercept may be plagued by slower-than-expected enrollment of its Phase III trial for Ocaliva. A recent Biomedtracker survey finds liver docs may be more positively inclined toward the Gilead candidate.

Combination Strategies A Common Thread In NASH R&D

Intercept continues to lead the non-alcoholic steatohepatitis race, but some analysts think Gilead is making up ground; data presented at AASLD shows those two, along with Allergan/Tobira and Bristol, are jockeying to produce combination regimens for the unmet medical need.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC098007

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel